Immunocore CEO: 3rd Big Pharma Eying Unique Cancer Targeting Tech

By Dan Stanton

- Last updated on GMT

Related tags: Big pharma, Cancer, Immune system

Immunocore is looking for more licensees for its cancer targeting technology following recent discovery and development deals with GSK and Genentech.

The Oxford, UK-based biotech company has developed a platform of bi-specific biological drugs which target peptide-antigens on cancer cell, called ImmTACs (Immune mobilizing mTCR Against Cancer), using T Cell Receptors.

All cancer cells contain some form of peptide-antigens, CEO James Noble told and so it “should be a way of attacking many more cancers than with antibody targets,”​ which he added was where the industry has been focusing, though only about 10% of cancer cells have this ‘antibody flag.’

Nobel said the platform could represent the “dawn of a completely new way of finding cancer cells," ​adding that it has attracted industry attention because Big Pharma firms are constantly on the look out for new ways to identify new targets they can use to develop new antibody drugs for the $50bn a year market.

Within the last month this has certainly been the case with first a research collaboration and licensing agreement with Roche subsidiary, Genetech, and then a similar pipeline partnership with GSK, both worth potentially in excess of £200m ($300m) for Immunocore.

Now Noble says another deal with Big Pharma is expected by the end of the year. “Most of the big pharmaceutical companies haven’t failed to spot the fact we have done these two deals – the phone’s been going a lot.

“We don’t have the capacity to do 20 of these deals so we are really looking to do a third one within a year.”

Related news

Show more

Related products

show more

Small-Scale Cell Culture Perfusion Process

Small-Scale Cell Culture Perfusion Process

Eppendorf for Bioprocess – Solutions that grow with you | 29-Mar-2019 | Application Note

Perfusion cell culture processes promise advantages for industrial bioprocessing, like saving space, increasing volumetric productivity, achieving more...

Removing Aggregates of an Acidic Monoclonal Antibody

Removing Aggregates of an Acidic Monoclonal Antibody

Bio-Rad Laboratories | 22-Oct-2018 | Technical / White Paper

CHT Ceramic Hydroxyapatite Media/Resins are known as the industry gold standard for
impurity removal during monoclonal antibody (mAb) purification....

Single-Step Influenza and Dengue Virus Purification

Single-Step Influenza and Dengue Virus Purification

Bio-Rad Laboratories | 08-Oct-2018 | Application Note

CHT XT is the newest addition to the CHT family of media. It has been designed for superior physical robustness to ensure it can be used repeatedly over...

Related suppliers

Follow us


View more